White House's removal of AstraZeneca COVID-19 shot production from Emergent plant won't affect its dose output: official
Reuters
Published Apr 05, 2021 12:05PM ET
(Reuters) - The U.S. government's removal of AstraZeneca (NASDAQ:AZN) PLC's COVID-19 shot production from Emergent BioSolutions Inc's Baltimore manufacturing facility does not suggest it has any concerns about the vaccine's safety or effectiveness and will not impact its output of doses, a White House official said on Monday.
The U.S. Department of Health and Human Services ordered Johnson & Johnson (NYSE:JNJ) to take charge of production at Emergent and for Emergent to stop making AstraZeneca's shots after the contract manufacturer made an error that ruined 15 million J&J COVID-19 vaccine doses.
"This is a decision that HHS made with Johnson & Johnson and AstraZeneca in complete collaboration," White House COVID-19 adviser Andy Slavitt told reporters during a press conference.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.